Brought to you by:
Open surgical bypass to distal targets at the ankle is ‘viable’ infrapopliteal CLTI treatment
The Vascular and Endovascular Surgical Society (VESS) Paper Session at the Vascular Annual Meeting (VAM) in Boston on Wednesday, June 15, will see Othman M. Abdul-Malak, MD, from the University of Pittsburgh Medical Center in Pittsburgh, deliver results from “Midterm…
Revascularization strategy for BTK intervention should hinge on diagnostic modality, LINC hears
New data provide “another argument” for the use of intravascular ultrasound (IVUS) in below-the-knee (BTK) interventions. This is according to Michael Lichtenberg, MD, from Arnsberg Vascular Center in Arnsberg, Germany, who presented one-year outcomes from the PRESTIGE pilot study at the…
Register today for two SVS courses
Registration has opened—along with early-bird pricing—for two Society for Vascular Surgery (SVS) in-person courses in coding and reimbursement, and peripheral artery disease (PAD) skills. Both will be held in October after being postponed in 2021 because of a surge in…
Medtronic gains FDA nod for IN.PACT 018 DCB
Medtronic has announced approval from the Food and Drug Administration (FDA) for the IN.PACT 018 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter, a drug-coated balloon (DCB), indicated for the interventional treatment of peripheral arterial disease (PAD) in the superficial femoral…
New long-term data of paclitaxel devices continue to show no increased mortality compared to non-drug coated devices
New long-term data from the SAFE-PAD (Safety assessment of femoropopliteal endovascular treatment with paclitaxel-coated devices) study were presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions (May 19–22) in Atlanta. The analysis…
Shockwave IVL maintains ‘superiority’ to angioplasty in calcified peripheral disease at two years
Shockwave Medical announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with intravascular lithotripsy (IVL) led to excellent long-term outcomes out to two years with preservation of future treatment options compared to percutaneous transluminal angioplasty (PTA)…
Tissue samples show paclitaxel effect in minority of CLTI patients receiving DCB angioplasty, study finds
Paclitaxel effect was witnessed in tissue specimens of a minority of chronic limb-threatening ischemia (CLTI) patients treated with drug-coated balloons (DCBs)—but was not dependent on DCB type, nor the dose level of the drug administered, and was not associated with…
The top 10 most popular Vascular Specialist stories in March
Among the posts catching Vascular Specialist readers’ eyes last month were the digital flipbook version of our March print edition, a new study looking at the Society for Vascular Surgery (SVS) open abdominal aortic aneurysm (AAA) recommendations, and an interview…
Alucent Biomedical announces first patient enrolled in first-in-human natural vascular scaffolding clinical trial
Alucent Biomedical announced in a press release that it has enrolled the first patient in ACTIVATE II, an Australia-based first-in-human clinical trial to evaluate the safety and efficacy of its natural vascular scaffolding (AlucentNVS) technology. The therapy is designed to open…
Shockwave Medical announces global launch of new peripheral IVL catheter
Shockwave Medical has announced the global commercial availability of the Shockwave M5+ peripheral intravascular lithotripsy (IVL) catheter after receiving both Food and Drug Administration (FDA) and CE mark clearance. A company press release details that the Shockwave M5+ catheter is specifically designed to…